Postpartum hemorrhage: Difference between revisions
(→Tone) |
|||
(21 intermediate revisions by 5 users not shown) | |||
Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*Leading cause of maternal death worldwide | |||
===Causes=== | ===Causes=== | ||
*Uterine atony (responsible for 80% of cases) | *Uterine atony (responsible for 80% of cases) | ||
Line 13: | Line 13: | ||
*Usually within 24 hours of delivery | *Usually within 24 hours of delivery | ||
*If occurs more than 24 hours after delivery, consider: retained POC, coagulopathy, etc | *If occurs more than 24 hours after delivery, consider: retained POC, coagulopathy, etc | ||
*Other pertinent definitions<ref>WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017 Apr 26. pii: S0140-6736(17)30638-4.</ref>: | |||
**> 1000 ml after c-section | |||
**Any blood loss to compromising hemodynamic stability | |||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
{{Postpartum emergencies DDX}} | {{Postpartum emergencies DDX}} | ||
== | ==Evaluation== | ||
===Work-up=== | ===Work-up=== | ||
*CBC | *CBC | ||
Line 29: | Line 32: | ||
*[[Fluid resuscitation]] | *[[Fluid resuscitation]] | ||
*Consider Blood Products for Hemodynamic Instability | *Consider Blood Products for Hemodynamic Instability | ||
* | *Early tranexamic acid (TXA) reduces death due to bleeding<ref>Ducloy-Bouthors AS et al. High-dose tranexamic acid reduces blood loss in postpartum haemorrhage. Crit Care. 2011;15(2):R117.</ref><ref>WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017 Apr 26. pii: S0140-6736(17)30638-4.</ref> | ||
**Give as soon as possible relative to bleeding onset | |||
** | **1 g IV of TXA over 10 min, with 2nd dose 30 min later if continual bleed '''OR''' bleed restarts within 24 hrs after 1st dose<ref>Shakur H et al. The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. Trials. 2010 Apr 16;11:40.</ref> | ||
**No difference between placebo and TXA in adverse events, including thromboembolism | |||
**All-cause mortality and hysterectomy not reduced with TXA | |||
*Evaluate placenta for retained products | *Evaluate placenta for retained products | ||
*Examine for tears under good lighting and suction | *Examine for tears under good lighting and suction | ||
Line 40: | Line 45: | ||
*Bimanual Massage | *Bimanual Massage | ||
*[[Oxytocin]] (Pitocin) | *[[Oxytocin]] (Pitocin) | ||
**1st line and most important drug - '''Oxytocin 80 units in 500 cc NS bag''', run it wide open<ref>Tita AT et al. Higher-dose oxytocin and hemorrhage after vaginal delivery: a randomized controlled trial. Obstet Gynecol. 2012 Feb;119(2 | **1st line and most important drug - '''Oxytocin 80 units in 500 cc NS bag''', run it wide open<ref>Tita AT et al. Higher-dose oxytocin and hemorrhage after vaginal delivery: a randomized controlled trial. Obstet Gynecol. 2012 Feb;119(2 Patient 1):293-300.</ref> | ||
**OR 20 MILLIunits/min IV after placenta delivery (rapid administration may cause hypotension) | **'''OR''' 20 MILLIunits/min IV after placenta delivery (rapid administration may cause hypotension) | ||
**OR 10 units IM if no IV | **'''OR''' 10 units IM if no IV | ||
*[[Misoprostol]] (Cytotec) 600mcg SL or 1000 mcg rectally | *[[Misoprostol]] (Cytotec) 600mcg SL or 1000 mcg rectally | ||
*[[Methylergonovine]] (Methergine) 0.2mg IM q2-4 hrs (relative contraindication in | *[[Methylergonovine]] (Methergine) 0.2mg IM q2-4 hrs (relative contraindication in patients with hypertension or [[Preeclampsia]] - may consider in severely unstable BP) | ||
*[[Carboprost]] (Hemabate) 250mcg IM q15 min (avoid in | *[[Carboprost]] (Hemabate) 250mcg IM q15 min (avoid in patients with asthma) | ||
*Bakri balloon placement, fill with warm | *Bakri balloon placement, fill with warm 500ml NS (or large/multiple Foleys or pack) - use US to place to top of fundus and ensure no retained placenta | ||
===Trauma=== | ===Trauma=== | ||
*''Genital tract tear'' | *''Genital tract tear'' | ||
**Suture [[lacerations]] - figure of eight with 3-0 or 2-0 absorbable | **Suture [[lacerations]] - figure of eight with 3-0 or 2-0 absorbable | ||
**Deep lacerations such as those by the cervix may require OR | **Deep lacerations such as those by the cervix may require '''OR''' | ||
**Drain hematomas >3 cm | **Drain hematomas >3 cm | ||
*''[[Uterine inversion]]'' | *''[[Uterine inversion]]'' | ||
**Manually replace placenta OR do not remove placenta until uterus has been replaced: | **Manually replace placenta '''OR''' do not remove placenta until uterus has been replaced: | ||
**Place hand inside the vagina and push the fundus cephalad along long axis of vagina | **Place hand inside the vagina and push the fundus cephalad along long axis of vagina | ||
**Prompt replacement important since cervix contracts over time creating a constriction ring | **Prompt replacement important since cervix contracts over time creating a constriction ring | ||
**Discontinue uterotonic meds (oxytocin) if uterus not reduced, and consider uterine relaxant options | **Discontinue uterotonic meds (oxytocin) if uterus not reduced, and consider uterine relaxant options:<ref>Rosen's Emergency Medicine - Concepts and Clinical Practice. 8th ed. 2013. Chapter 181: Labor and Delivery and their Complications. 2349.</ref>: | ||
***[[Nitroglycerine]] IV 50-250 mcg bolus over 1-2 min, then up to x3-4 additional doses q3-5 min to relax uterus | ***[[Nitroglycerine]] IV 50-250 mcg bolus over 1-2 min, then up to x3-4 additional doses q3-5 min to relax uterus | ||
***[[Magnesium]] 4-6 g IV over 15 min | ***[[Magnesium]] 4-6 g IV over 15 min | ||
***[[Terbutaline]] 0. | ***[[Terbutaline]] 0.25mg IV or SQ | ||
**After replacement: | **After replacement: | ||
***Fundal massage ± bimanual massage/compression | ***Fundal massage ± bimanual massage/compression | ||
Line 91: | Line 96: | ||
{{#widget:YouTube|id=dz2gYz4FQcY}} | {{#widget:YouTube|id=dz2gYz4FQcY}} | ||
[[Category: | [[Category:OBGYN]] |
Revision as of 06:07, 6 March 2019
Background
- Leading cause of maternal death worldwide
Causes
- Uterine atony (responsible for 80% of cases)
- Retained placental tissue
- Lower genital tract lacerations
- Uterine rupture
- Uterine inversion
- Underlying coagulation abnormalities
Clinical Features
- Loss of >500 mL blood after vaginal delivery
- Usually within 24 hours of delivery
- If occurs more than 24 hours after delivery, consider: retained POC, coagulopathy, etc
- Other pertinent definitions[1]:
- > 1000 ml after c-section
- Any blood loss to compromising hemodynamic stability
Differential Diagnosis
3rd Trimester/Postpartum Emergencies
- Acute fatty liver of pregnancy
- Amniotic fluid embolus
- Chorioamnionitis
- Eclampsia
- HELLP syndrome
- Mastitis
- Peripartum cardiomyopathy
- Postpartum endometritis (postpartum PID)
- Postpartum headache
- Postpartum hemorrhage
- Preeclampsia
- Resuscitative hysterotomy
- Retained products of conception
- Septic abortion
- Uterine rupture
Evaluation
Work-up
- CBC
- Coags
- Type and cross
Evaluation
- Clinical diagnosis
Management
- Fluid resuscitation
- Consider Blood Products for Hemodynamic Instability
- Early tranexamic acid (TXA) reduces death due to bleeding[2][3]
- Give as soon as possible relative to bleeding onset
- 1 g IV of TXA over 10 min, with 2nd dose 30 min later if continual bleed OR bleed restarts within 24 hrs after 1st dose[4]
- No difference between placebo and TXA in adverse events, including thromboembolism
- All-cause mortality and hysterectomy not reduced with TXA
- Evaluate placenta for retained products
- Examine for tears under good lighting and suction
- Treat underlying cause - 4T's: Tone, Trauma, Tissue, Thrombosis
Tone
Uterine atony (boggy uterus)
- Bimanual Massage
- Oxytocin (Pitocin)
- 1st line and most important drug - Oxytocin 80 units in 500 cc NS bag, run it wide open[5]
- OR 20 MILLIunits/min IV after placenta delivery (rapid administration may cause hypotension)
- OR 10 units IM if no IV
- Misoprostol (Cytotec) 600mcg SL or 1000 mcg rectally
- Methylergonovine (Methergine) 0.2mg IM q2-4 hrs (relative contraindication in patients with hypertension or Preeclampsia - may consider in severely unstable BP)
- Carboprost (Hemabate) 250mcg IM q15 min (avoid in patients with asthma)
- Bakri balloon placement, fill with warm 500ml NS (or large/multiple Foleys or pack) - use US to place to top of fundus and ensure no retained placenta
Trauma
- Genital tract tear
- Suture lacerations - figure of eight with 3-0 or 2-0 absorbable
- Deep lacerations such as those by the cervix may require OR
- Drain hematomas >3 cm
- Uterine inversion
- Manually replace placenta OR do not remove placenta until uterus has been replaced:
- Place hand inside the vagina and push the fundus cephalad along long axis of vagina
- Prompt replacement important since cervix contracts over time creating a constriction ring
- Discontinue uterotonic meds (oxytocin) if uterus not reduced, and consider uterine relaxant options:[6]:
- Nitroglycerine IV 50-250 mcg bolus over 1-2 min, then up to x3-4 additional doses q3-5 min to relax uterus
- Magnesium 4-6 g IV over 15 min
- Terbutaline 0.25mg IV or SQ
- After replacement:
- Fundal massage ± bimanual massage/compression
- Then oxytocin infusion with 40 units in 1 L of NS at 200-1000 cc/hr
Tissue
Retained placental tissue
- Pelvic exam may be normal other than blood
- Detect with US
- Manual removal
- Curettage
Thrombin
Reverse any coagulopathies
- Labs - platelets, coags, fibrinogen, d-dimer
- Replace appropriate blood components
Disposition
- Admit
See Also
References
- ↑ WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017 Apr 26. pii: S0140-6736(17)30638-4.
- ↑ Ducloy-Bouthors AS et al. High-dose tranexamic acid reduces blood loss in postpartum haemorrhage. Crit Care. 2011;15(2):R117.
- ↑ WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017 Apr 26. pii: S0140-6736(17)30638-4.
- ↑ Shakur H et al. The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. Trials. 2010 Apr 16;11:40.
- ↑ Tita AT et al. Higher-dose oxytocin and hemorrhage after vaginal delivery: a randomized controlled trial. Obstet Gynecol. 2012 Feb;119(2 Patient 1):293-300.
- ↑ Rosen's Emergency Medicine - Concepts and Clinical Practice. 8th ed. 2013. Chapter 181: Labor and Delivery and their Complications. 2349.
Video
{{#widget:YouTube|id=dz2gYz4FQcY}}